1. Home
  2. HLN vs ARGX Comparison

HLN vs ARGX Comparison

Compare HLN & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HLN
  • ARGX
  • Stock Information
  • Founded
  • HLN 2022
  • ARGX 2008
  • Country
  • HLN United Kingdom
  • ARGX Netherlands
  • Employees
  • HLN N/A
  • ARGX N/A
  • Industry
  • HLN Package Goods/Cosmetics
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HLN Consumer Discretionary
  • ARGX Health Care
  • Exchange
  • HLN Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • HLN 48.2B
  • ARGX 44.2B
  • IPO Year
  • HLN N/A
  • ARGX 2017
  • Fundamental
  • Price
  • HLN $9.70
  • ARGX $756.83
  • Analyst Decision
  • HLN Buy
  • ARGX Strong Buy
  • Analyst Count
  • HLN 1
  • ARGX 19
  • Target Price
  • HLN $10.95
  • ARGX $777.83
  • AVG Volume (30 Days)
  • HLN 7.8M
  • ARGX 360.8K
  • Earning Date
  • HLN 07-31-2025
  • ARGX 10-30-2025
  • Dividend Yield
  • HLN 1.86%
  • ARGX N/A
  • EPS Growth
  • HLN 41.64
  • ARGX N/A
  • EPS
  • HLN 0.23
  • ARGX 18.75
  • Revenue
  • HLN $15,096,588,575.00
  • ARGX $3,120,821,000.00
  • Revenue This Year
  • HLN $1.38
  • ARGX $80.01
  • Revenue Next Year
  • HLN $4.24
  • ARGX $30.64
  • P/E Ratio
  • HLN $42.37
  • ARGX $35.87
  • Revenue Growth
  • HLN N/A
  • ARGX 88.04
  • 52 Week Low
  • HLN $8.86
  • ARGX $510.06
  • 52 Week High
  • HLN $11.42
  • ARGX $779.03
  • Technical
  • Relative Strength Index (RSI)
  • HLN 46.61
  • ARGX 74.39
  • Support Level
  • HLN $9.77
  • ARGX $745.82
  • Resistance Level
  • HLN $9.92
  • ARGX $779.03
  • Average True Range (ATR)
  • HLN 0.12
  • ARGX 14.92
  • MACD
  • HLN 0.01
  • ARGX 1.39
  • Stochastic Oscillator
  • HLN 37.04
  • ARGX 74.14

About HLN Haleon plc (Each representing two)

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: